AbbVie - United States News Beep

AbbVie (NYSE: ABBV), one of the world’s largest pharmaceutical companies, is usually considered a blue chip dividend stock…

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…

Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…

NEW YORK (AP) — U.S. stocks are drifting near their records in mixed trading Monday after trading resumed…

Quick Read NVO sits 44% below its 52-week high with a price-to-free-cash-flow of 5 and a free cash…

Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…

It’s safe to say the healthcare sector isn’t renowned as a repository of dividend-paying companies. Yet some not…

Equity markets have moved in the wrong direction over the past three weeks. They may not rebound and…

Verizon (VZ) yields 5.4% at its current price, paying $0.69 per quarter and offering higher current income for…

Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie’s immunosuppressant portfolio…

AbbVie has a solid business capable of performing well even in bad times. The company has proven that…

With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly…